Are advanced oxidation protein products potential uremic toxins?

Kidney International, Supplement

Volumn 63, Issue 84, 2003, Pages

  Witko Sarsat, Véronique ^a   Gausson, Valérie ^a   Descamps Latscha, Béatrice ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Inflammation; Myeloperoxidase; Phagocyte

Indexed keywords

CYTOKINE; MYELOPEROXIDASE; UREMIC TOXIN; ADVANCED GLYCATION END PRODUCT; TOXIN;

ANTIOXIDANT ACTIVITY; CHLORINATION; CHRONIC KIDNEY FAILURE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CYTOKINE PRODUCTION; HEMODIALYSIS; HUMAN; INFLAMMATION; MONOCYTE; NEUTROPHIL; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; UREMIA; METABOLISM; REVIEW;

GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; TOXINS, BIOLOGICAL; UREMIA;

EID: 0037406364     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s84.47.x     Document Type: Conference Paper

References (19)

1. DESCAMPS-LATSCHA B, DRUEKE T, WITKO-SARSAT V: Dialysis-induced oxidative stress: Biological aspects, clinical consequences, and therapy. Semin Dial 14:193-199, 2001
2. WITKO-SARSAT V, RIEU P, DESCAMPS-LATSCHA B, et al: Neutrophils: Molecules, functions and pathophysiological aspects. Lab Invest 80:617-653, 2000
3. KLEBANOFF SJ: Myeloperoxidase. Proc Assoc Am Physicians 111:383-389, 1999
4. HEINECKE JW: Atherosclerosis: Cell biology and lipoproteins. Curr Opin Lipidol 7:U131-U136, 1996
5. HAZELL LJ, ARNOLD L, FLOWERS D, et al: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 97:1535-1544, 1996
6. CANAUD B, CRISTOL J, MORENA M, et al: Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 17:99-106, 1999
7. HORL WH: Neutrophil function in renal failure. Adv Nephrol Necker Hosp 31:173-192, 2001
8. DESCAMPS-LATSCHA B, HERBELIN A, NGUYEN AT, et al: Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 154:882-892, 1995
9. STENVINKEL P, HEIMBURGER O, PAULTRE F, et al: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55:1899-1911, 1999
10. DAVIES KJ: Protein damage and degradation by oxygen radicals. I. General aspects. J Biol Chem 262:9895-9901, 1987
11. WITKO-SARSAT V, FRIEDLANDER M, CAPEILLERE-BLANDIN C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996
12. VLASSARA H: Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 12:54-59, 1994
13. VANHOLDER R, ARGILES A, BAURMEISTER U, et al: Uremic toxicity: Present state of the art. Int J Artif Organs 24:695-725, 2001
14. KANEDA H, TAGUCHI J, OGASAWARA K, et al: Increased level of advanced oxidation protein products in patients with coronary heart disease. Atherosclerosis 162:221-225, 2002
15. WRATTEN ML, SERENI L, TETTA C: Hemolipodialysis attenuates oxidative stress and removes hydrophobic toxins. Artif Organs 24:685-690, 2000
16. BUONOCORE G, PERRONE S, LONGINI M, et al: Oxidative stress in preterm neonates at birth and on the seventh day of life. Pediatr Res 52:46-49, 2002
17. WITKO-SARSAT V, FRIEDLANDER M, NGUYEN KHOA T, et al: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524-2532, 1998
18. WITKO-SARSAT V, GAUSSON V, NGUYEN AT, et al: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 63, In press.
19. DRUEKE T, WITKO-SARSAT V, MASSY ZA, et al: Iron therapy, advanced oxidation protein products and carotid intima media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002